A detailed history of Bray Capital Advisors transactions in Eli Lilly & CO stock. As of the latest transaction made, Bray Capital Advisors holds 7,545 shares of LLY stock, worth $6.69 Million. This represents 1.77% of its overall portfolio holdings.

Number of Shares
7,545
Previous 7,545 -0.0%
Holding current value
$6.69 Million
Previous $5.87 Million 16.39%
% of portfolio
1.77%
Previous 1.54%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

May 03, 2021

BUY
$164.32 - $212.72 $7,394 - $9,572
45 Added 0.6%
7,545 $1.41 Million
Q3 2019

Oct 29, 2019

SELL
$106.79 - $116.16 $106,790 - $116,160
-1,000 Reduced 11.76%
7,500 $839,000
Q1 2018

May 04, 2018

SELL
$74.21 - $87.6 $109,979 - $129,823
-1,482 Reduced 14.85%
8,500 $658,000
Q3 2017

Nov 01, 2017

BUY
$77.07 - $85.54 $769,312 - $853,860
9,982
9,982 $854,000

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $843B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Bray Capital Advisors Portfolio

Follow Bray Capital Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bray Capital Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Bray Capital Advisors with notifications on news.